Featured Research

from universities, journals, and other organizations

New Upper Limit Defined For Normal ALT In Adolescent Males

Date:
December 3, 2007
Source:
Wiley-Blackwell
Summary:
A new study of adolescent offenders in Australia has identified an upper limit for ALT that is more sensitive for the diagnosis of liver disease. The findings could facilitate targeted interventions for the youths in this group, who are at high risk for HCV infection and obesity-related liver disease.

A new cohort study of adolescent offenders in Australia has identified an upper limit for ALT that is more sensitive for the diagnosis of liver disease. The findings could facilitate targeted interventions for the youths in this group, who are at high risk for HCV infection and obesity-related liver disease.

Few studies have examined the liver health of at-risk adolescents, or reported associations between liver biochemistry and hepatitis C virus or metabolic liver disease. Researchers Dr David van der Poorten and Professors Dianna Kenny and Jacob George of Sydney University, analyzed data from a large cohort of young male offenders under supervision by the New South Wales Department of Juvenile Justice in Australia, who took part in a comprehensive health study, funded by the Australian Research Council, NSW Department of Juvenile Justice and Justice Health.

The researchers sought to create a new definition for the normal upper limit of liver biochemistry; to define the associations and implications of raised ALT; and to understand the risk factors and associations with hepatitis C.

They examined the results of liver tests and lipid studies from blood samples of 439 young male offenders serving community orders who agreed to participate in the health survey between October 2003 and December 2005. They also considered clinical, demographic, and lifestyle data and performed statistical analyses to determine relevant associations.

They determined the upper limit of normal for liver enzymes using the liver tests of the participants at lowest risk of liver disease. These young men had normal BMI, cholesterol, triglycerides, and blood pressure; and did not have hepatitis B or C infection, or high alcohol consumption. The researchers determined that the upper limit of normal was 28 IU/L for ALT; 32 IU/L for AST; and 29 IU/L for GGT. These are significantly lower than current upper limits for these tests which usually range from 45-55 IU/L.

Applying these cutoffs to all participants, they found that 17 percent had raised ALT, and compared to those with normal ALT, "there was a strong association for overweight or obesity," the authors report. "To prevent further hepatic damage and to minimize cardiovascular and diabetes risk, targeted interventions in adolescents at the earliest stages of metabolic dysfunction are a particularly high priority."

The new upper limits also detected 80 percent of the HCV-infected patients, who were significantly more likely to have injected drugs in the last 12 months. A one-year follow-up blood test of 81 of the original participants showed additional incidents of HCV antibodies, suggesting a new infection rate of at least 3.7 percent per year.

The results indicate a concerning level of HCV exposure among this population. "Hence, greater education regarding blood borne viruses, risk factors for transmission and implementing harm minimization strategies in this population is crucial," the authors write. They also suggest routine hepatitis B vaccination.

"In conclusion," they write, "this study has provided a wealth of clinical and health related data relevant to adolescents. The new definition of normal adolescent ALT allows greater sensitivity in diagnosing early liver disease. By identifying those with hepatitis B, C and obesity related liver disease; targeted interventions can and should be implemented to minimize future health-related morbidity."

Article: "Liver Disease in Adolescents: A Cohort Study of High-Risk Individuals." Van der Poorten, David; Kenny, Dianna; Butler, Tony; George, Jacob. Hepatology; December 2007; (DOI: 10.1002/hep.21918).


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "New Upper Limit Defined For Normal ALT In Adolescent Males." ScienceDaily. ScienceDaily, 3 December 2007. <www.sciencedaily.com/releases/2007/12/071203164744.htm>.
Wiley-Blackwell. (2007, December 3). New Upper Limit Defined For Normal ALT In Adolescent Males. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/12/071203164744.htm
Wiley-Blackwell. "New Upper Limit Defined For Normal ALT In Adolescent Males." ScienceDaily. www.sciencedaily.com/releases/2007/12/071203164744.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins